$0.60 14.3%
ASLN Stock Price vs. AI Score
Data gathered: November 27

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Aslan Pharmaceuticals (ASLN)

Analysis generated March 19, 2024. Powered by Chat GPT.

Aslan Pharmaceuticals is a biotech company focused on the development of treatments for cancer and other immune disorders. Uppon its inception, Aslan has been targeting unmet medical needs in the Asia Pacific region and increasingly on a global scale. The company's pipeline includes innovative therapeutics that are being developed to fight a range of diseases with high incidence rates. Biotech firms like Aslan are usually heavily reliant on the successful development, regulatory approval, and commercialization of their lead product candidates.

Read full AI stock Analysis

Stock Alerts - Aslan Pharmaceuticals (ASLN)

company logo Aslan Pharmaceuticals | September 25
Employee Rating is up by 4.8% over the last month.
company logo Aslan Pharmaceuticals | July 18
Price is down by -8.6% in the last 24h.
company logo Aslan Pharmaceuticals | July 17
Price is down by -53.2% in the last 24h.
company logo Aslan Pharmaceuticals | July 16
Price is down by -11.6% in the last 24h.

About Aslan Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.


Aslan Pharmaceuticals
Price $0.60
Target Price Sign up
Volume 806,350
Market Cap $1.7M
Year Range $0.6 - $5.56
Dividend Yield 0%
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24000-9.9M-9.3M-0.780
Q4 '23000-14M0-0.780
Q3 '23000-9.7M-8.5M-0.560
Q2 '2312M012M-9.7M-8.5M-0.110
Q1 '23000-19M-18M-1.290

What is the Market Cap of Aslan Pharmaceuticals?

The Market Cap of Aslan Pharmaceuticals is $1.7M.

What is the current stock price of Aslan Pharmaceuticals?

Currently, the price of one share of Aslan Pharmaceuticals stock is $0.60.

How can I analyze the ASLN stock price chart for investment decisions?

The ASLN stock price chart above provides a comprehensive visual representation of Aslan Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Aslan Pharmaceuticals shares. Our platform offers an up-to-date ASLN stock price chart, along with technical data analysis and alternative data insights.

Does ASLN offer dividends to its shareholders?

As of our latest update, Aslan Pharmaceuticals (ASLN) does not offer dividends to its shareholders. Investors interested in Aslan Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Aslan Pharmaceuticals?

Some of the similar stocks of Aslan Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.